Abstract
In IPATential150 (NCT03072238), ipat + abi as first-line mCRPC treatment (tx) significantly reduced the risk for disease worsening or death vs placebo (pbo) + abi in patients (pts) with tumours with PTEN loss status by IHC (HR, 0.77; 95% CI: 0.61, 0.98; P = 0.034) but not in the ITT population (de Bono ESMO 2020). Ipat + abi had a safety profile consistent with each agent’s known toxicities. Here, we further characterise the nature and manageability of AEs associated with ipat and abi from IPATential150, the first Ph III trial of AKT plus androgen biosynthesis inhibition for mCRPC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
